ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

ALCJ Crossject

2.02
0.01 (0.50%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Crossject ALCJ Euronext Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.01 0.50% 2.02 01:35:21
Open Price Low Price High Price Close Price Previous Close
2.025 1.99 2.05 2.02 2.01
more quote information »

Recent News

Date Time Source Heading
25/4/202415:32GLOBECrossject communique ses résultats financiers audités pour..
11/4/202400:30GLOBECrossject : Information relative au nombre total de droits..
03/4/202403:35GLOBECrossject trading on Euronext to resume as usual on..
02/4/202419:30GLOBECrossject poursuit sa stratégie de développement aux..
08/3/202417:30GLOBELe Score de l’index Egalité femmes-hommes chez Crossject..
27/2/202418:30GLOBECrossject obtient un financement jusqu’à 12 millions d’euros..
07/2/202403:30GLOBECrossject provides strategic update on priorities for 2024
02/2/202404:15GLOBECrossject organisera un webcast le 6 février à 17h30 pour..
17/1/202403:15GLOBECrossject : Information relative au nombre total de droits..
10/1/202402:21GLOBECrossject annonce l’initiation de la couverture de son titre..
05/1/202404:00GLOBECrossject engage Syneos Health pour le lancement commercial..
22/12/202317:30GLOBECrossject signe un accord de commercialisation pour..
21/12/202302:40GLOBECrossject : Information relative au nombre total de droits..
28/11/202317:30GLOBECrossject announces initiation of coverage by ODDO BHF
15/11/202303:35GLOBECrossject : Information relative au nombre total de droits..
05/10/202317:45GLOBECrossject : Information relative au nombre total de droits..
27/9/202301:35GLOBECrossject reports financial results and business highlights..
12/9/202301:35GLOBECrossject : Information relative au nombre total de droits..
11/9/202315:30GLOBECrossject annonce une nouvelle nette amélioration de sa..
05/9/202321:00GLOBECrossject reports successful completion of European and U.S...
05/9/202315:30GLOBECrossject reports successful completion of European and U.S...
09/8/202301:49GLOBECrossject : Information relative au nombre total de droits..
25/7/202302:00GLOBECrossject : Information relative au nombre total de droits..
21/7/202300:55GLOBECrossject signs new licensing agreement on ZENEO® Midazolam..
20/7/202315:30GLOBECrossject signs new licensing agreement on ZENEO® Midazolam..
11/7/202302:00GLOBECROSSJECT - Information relative au nombre total de droits..
30/6/202316:30GLOBECrossject répond aux questions posées par les actionnaires..
13/6/202302:00GLOBECrossject à l'écoute de ses actionnaires individuels et des..
06/6/202302:00GLOBECROSSJECT - Information relative au nombre total de droits..
02/6/202302:30GLOBECrossject - Nomination de Daniel Teper au Conseil de..
11/5/202302:00GLOBECrossject : Information relative au nombre total de droits..
29/4/202302:27GLOBECrossject - Mise à disposition du rapport financier annuel..
29/4/202302:16GLOBECrossject - Rapport financier annuel 2022

Your Recent History

Delayed Upgrade Clock